8-chloroadenosine-3',5'-cyclic monophosphorothioate has been researched along with adenosine in 1 studies
| Studies (8-chloroadenosine-3',5'-cyclic monophosphorothioate) | Trials (8-chloroadenosine-3',5'-cyclic monophosphorothioate) | Recent Studies (post-2010) (8-chloroadenosine-3',5'-cyclic monophosphorothioate) | Studies (adenosine) | Trials (adenosine) | Recent Studies (post-2010) (adenosine) |
|---|---|---|---|---|---|
| 17 | 0 | 1 | 32,536 | 1,075 | 8,930 |
| Protein | Taxonomy | 8-chloroadenosine-3',5'-cyclic monophosphorothioate (IC50) | adenosine (IC50) |
|---|---|---|---|
| high affinity choline transporter 1 isoform a | Homo sapiens (human) | 0.3851 | |
| Sodium/nucleoside cotransporter 1 | Homo sapiens (human) | 5.5 | |
| Sodium/nucleoside cotransporter 2 | Homo sapiens (human) | 5.5 | |
| Adenosine receptor A3 | Homo sapiens (human) | 0.0011 | |
| Adenosine receptor A1 | Homo sapiens (human) | 0.0023 | |
| Equilibrative nucleoside transporter 1 | Homo sapiens (human) | 63 | |
| Solute carrier family 28 member 3 | Homo sapiens (human) | 3.3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Christie, MJ; Hack, SP; Vaughan, CW | 1 |
1 other study(ies) available for 8-chloroadenosine-3',5'-cyclic monophosphorothioate and adenosine
| Article | Year |
|---|---|
Modulation of GABA release during morphine withdrawal in midbrain neurons in vitro.
Topics: Action Potentials; Adenosine; Affinity Labels; Animals; Colforsin; Cyclic AMP; Dipyridamole; Dose-Response Relationship, Drug; Drug Interactions; Enkephalins; Enzyme Inhibitors; gamma-Aminobutyric Acid; In Vitro Techniques; Isoquinolines; Male; Mesencephalon; Mice; Mice, Inbred C57BL; Morphine; Morphine Dependence; Naloxone; Narcotic Antagonists; Narcotics; Neural Inhibition; Neurons; Patch-Clamp Techniques; Periaqueductal Gray; Probenecid; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Substance Withdrawal Syndrome; Sulfonamides; Synaptic Transmission; Thioinosine; Time Factors; Uricosuric Agents; Vasodilator Agents; Xanthines | 2003 |